Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC

C. Pinto, N. Normanno, A. Orlandi, F. Fenizia, A. Damato, E. Maiello, E. Tamburini, F. Di Costanzo, G. Tonini, D. Bilancia, D. Corsi, S. Pisconti, F. Ferrau, S. Gori, B. Daniele, A. Zaniboni, H. Soto Parra, G.L. Frassinetti, R.V. Iaffaioli, A. CassataM.G. Zampino, L. Repetto, M.A. Calegari, C. Barone

Research output: Contribution to journalArticle

Original languageEnglish
Pages (from-to)1339-1346
Number of pages8
JournalFuture Oncology
Volume14
Issue number14
DOIs
Publication statusPublished - 2018

Cite this

Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC. / Pinto, C.; Normanno, N.; Orlandi, A.; Fenizia, F.; Damato, A.; Maiello, E.; Tamburini, E.; Di Costanzo, F.; Tonini, G.; Bilancia, D.; Corsi, D.; Pisconti, S.; Ferrau, F.; Gori, S.; Daniele, B.; Zaniboni, A.; Soto Parra, H.; Frassinetti, G.L.; Iaffaioli, R.V.; Cassata, A.; Zampino, M.G.; Repetto, L.; Calegari, M.A.; Barone, C.

In: Future Oncology, Vol. 14, No. 14, 2018, p. 1339-1346.

Research output: Contribution to journalArticle

Pinto, C, Normanno, N, Orlandi, A, Fenizia, F, Damato, A, Maiello, E, Tamburini, E, Di Costanzo, F, Tonini, G, Bilancia, D, Corsi, D, Pisconti, S, Ferrau, F, Gori, S, Daniele, B, Zaniboni, A, Soto Parra, H, Frassinetti, GL, Iaffaioli, RV, Cassata, A, Zampino, MG, Repetto, L, Calegari, MA & Barone, C 2018, 'Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC', Future Oncology, vol. 14, no. 14, pp. 1339-1346. https://doi.org/10.2217/fon-2017-0592
Pinto, C. ; Normanno, N. ; Orlandi, A. ; Fenizia, F. ; Damato, A. ; Maiello, E. ; Tamburini, E. ; Di Costanzo, F. ; Tonini, G. ; Bilancia, D. ; Corsi, D. ; Pisconti, S. ; Ferrau, F. ; Gori, S. ; Daniele, B. ; Zaniboni, A. ; Soto Parra, H. ; Frassinetti, G.L. ; Iaffaioli, R.V. ; Cassata, A. ; Zampino, M.G. ; Repetto, L. ; Calegari, M.A. ; Barone, C. / Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC. In: Future Oncology. 2018 ; Vol. 14, No. 14. pp. 1339-1346.
@article{9e8dfac2a6734b75aa9d0cd78820dbdc,
title = "Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC",
author = "C. Pinto and N. Normanno and A. Orlandi and F. Fenizia and A. Damato and E. Maiello and E. Tamburini and {Di Costanzo}, F. and G. Tonini and D. Bilancia and D. Corsi and S. Pisconti and F. Ferrau and S. Gori and B. Daniele and A. Zaniboni and {Soto Parra}, H. and G.L. Frassinetti and R.V. Iaffaioli and A. Cassata and M.G. Zampino and L. Repetto and M.A. Calegari and C. Barone",
note = "Export Date: 25 January 2019",
year = "2018",
doi = "10.2217/fon-2017-0592",
language = "English",
volume = "14",
pages = "1339--1346",
journal = "Future Oncology",
issn = "1479-6694",
publisher = "Future Medicine Ltd.",
number = "14",

}

TY - JOUR

T1 - Phase III study with FOLFIRI + cetuximab versus FOLFIRI + cetuximab followed by cetuximab alone in RAS and BRAF WT mCRC

AU - Pinto, C.

AU - Normanno, N.

AU - Orlandi, A.

AU - Fenizia, F.

AU - Damato, A.

AU - Maiello, E.

AU - Tamburini, E.

AU - Di Costanzo, F.

AU - Tonini, G.

AU - Bilancia, D.

AU - Corsi, D.

AU - Pisconti, S.

AU - Ferrau, F.

AU - Gori, S.

AU - Daniele, B.

AU - Zaniboni, A.

AU - Soto Parra, H.

AU - Frassinetti, G.L.

AU - Iaffaioli, R.V.

AU - Cassata, A.

AU - Zampino, M.G.

AU - Repetto, L.

AU - Calegari, M.A.

AU - Barone, C.

N1 - Export Date: 25 January 2019

PY - 2018

Y1 - 2018

U2 - 10.2217/fon-2017-0592

DO - 10.2217/fon-2017-0592

M3 - Article

VL - 14

SP - 1339

EP - 1346

JO - Future Oncology

JF - Future Oncology

SN - 1479-6694

IS - 14

ER -